We provide drug information and pharmaceutical management sheets for patients receiving cancer chemotherapy who have a high frequency of severe adverse reactions. The usefulness of these sheets was evaluated in a case study. After receiving the drug information sheets, the patients took an interest in the adverse reactions. Through the utilization of pharmaceutical management sheets that describe the adverse reactions that could occur, we were able to rapidly manage persistent abdominal flatulence in patients receiving the first course of CHOP therapy. After patients were given information on trime-butine, therapy for this adverse reaction was provided by the doctor and a drug for the mitigation of abdominal flatulence was co-administered during the second course of CHOP therapy. We consider that drug management using these forms has contributed greatly to the prevention of adverse reactions in patients receiving cancer chemotherapy.
